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What will Shane Crotty do next? Cur-
rently an assistant professor at the Uni-
versity of California, San Diego and an 
associate member of the La Jolla Insti-
tute for Allergy & Immunology (LIAI), 
he’s accomplished a lot in very little 
time. As a double major in biology and 
writing at MIT, Crotty began a biography 
of the Nobel prize-winning molecular 
biologist David Baltimore to fulfill his 
writing thesis requirement. This culmi-
nated with the 2001 publication of 
Ahead of the Curve while Crotty was a 
graduate student in Raul Andino’s labo-
ratory at the University of California, 
San Francisco (1). While he was there, 
he also determined that the antiviral 
drug ribavirin works by inducing lethal 
mutations in RNA virus genomes (2).
Now, Crotty’s laboratory at LIAI 
focuses on immunological memory and 
the immune response to vaccines and 
infectious diseases. Recently, they discov-
ered that one key to a long-lasting immune 
response is T cell expres-
sion of the protein SAP 
(SLAM-associated pro-
tein), which is needed to 
help B cells become long-
lived plasma cells or 
memory cells (3, 4). On a 
more practical level, he 
and his laboratory figured 
out that one reason the 
smallpox vaccine elicits 
such a strong protective 
antibody response is be-
cause it presents multiple 
antigenic targets to the immune system (5, 
6). With that knowledge, they produced a 
mélange of monoclonal antibodies for the 
National Institutes of Health to treat small-
pox in the event of a bioterrorist attack.
ATTAINING VACCINE GREATNESS
What is it that makes a really good 
vaccine really good?
There are about 25 licensed vaccines, and 
23 of them clearly work because of pro-
tective antibody responses. The smallpox 
vaccine is in that category. One reason the 
smallpox vaccine is such a good vaccine is 
that it drives protective antibody responses 
to several diff  erent targets on the virus. A 
diverse response is better than a magic 
bullet, or a single response. And this will 
probably also apply to large pathogens like 
bacteria and parasites, which have 
hundreds of surface antigens. Based on 
the smallpox vaccine model, being able to 
make responses to multiple antigens is 
probably the way to get really good 
protective immunity in a population.
Do all vaccines work the same way?
All vaccines are predicated on immuno-
logical memory. And almost all good 
antibody responses and memory antibody 
responses are dependent on CD4+ T cell 
help. So what is it about T cells that con-
trols the B cell response? SAP knockout 
mice can make an acute response, but 
they have no antibody memory, no B 
cell memory, and it’s because of a prob-
lem with their CD4+ T cells. There are 
humans with defects in the SAP gene, 
and they have the same problem.
We know that SAP is central to 
immunological memory, and so there-
fore it should be central to vaccine design. 
This has led us to interest in follicular 
helper CD4+ T cells, which are special-
ized to help B cells. We’re trying to 
understand this T cell subset and how 
SAP does or doesn’t relate to it. How do 
you really get T cells to help B cells so 
that you get good germinal centers and 
then a good memory response? We 
think it comes from the follicular helper 
CD4+ T cells. We’ve been working on 
it since I started my laboratory five years 
ago, and now it’s certainly a hot area.
SCOUT, AUTHOR, SCIENTIST
You listed the Eagle Scouts among your 
honors on your website. Do you ever get 
to use the skills that you learned as an 
Eagle Scout now that you’re grown up?
I do think that it’s really useful for devel-
oping leadership skills, because you 
have to be able to organize groups of 
people, whether you’re just doing 
projects or whatever.
Is it useful for laboratory management?
Yeah, I actually think so! Laboratory 
management is one of those tough 
things to learn. There aren’t that many 
ways to learn how to be a boss.
Do you think that working on Ahead of 
the Curve infl  uenced your decision to 
work on viruses and the immune response?
It did, but it was an inadvertent thing. 
I majored in biology and writing at MIT. 
So writing was a real part of what I was 
doing at the time. I did a biography of 
David Baltimore as my writing thesis. 
I wanted to write science for nonscien-
tists, and it’s very easy for that to end up 
being boring. Focusing on a given indi-
vidual is a great way to make it more 
exciting. Then in grad school I took a 
class on virology because I realized that it 
would make sense to know more about it 
for the writing I was doing. So I took this 
virology class and I was hooked.
Was it simple to combine writing and 
research?
That was challenging. I tried to do 
both at the same time, and I couldn’t. 
Virologist and published author Shane Crotty sees immune memory as the 
key to making a better vaccine.
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At an article level, I think it’s totally 
possible to write and do science at the 
same time. At a book level, it’s just im-
possible, in my opinion, if the book is 
a single entity. It just takes too long to 
wrap your head around the whole 
project, keep styles consistent, and re-
member what you were dealing with 
50 pages ago. So I tried to do both for 
a while, and then fi  nally I took two 
months off  , and later another month off  , 
where I just didn’t go to the laboratory 
at all.
Did your research have anything to do 
with the book?
Raul Andino, my graduate advisor, had 
been in David Baltimore’s laboratory. 
I was actually quite interested in avoid-
ing Baltimore connections initially, 
because I really considered the writing 
and the science separate. I wasn’t a 
Baltimore groupie. But it turned out 
there were basically two virologists at 
UCSF, and one of them told me his 
laboratory was full, and the other was 
Raul. So it’s just sort of the way it 
played out.
Are you working on any writing projects 
right now?
I’m not. I consider it off   and on, but 
running a laboratory is more than a full-
time job, so it’s just not practical. And 
defi  nitely a book isn’t practical because 
it takes a huge amount of time. So, no, 
it’s pretty much all paper writing.
What do you do for fun when you’re not 
in the laboratory?
Play with my kids. My daughter was 
born six months before I started my lab-
oratory, and my son was born two years 
later. So it’s been a very busy fi  ve years.
BIODEFENSE STRATEGIES
Are any of the discoveries you’ve made 
about the immune response to the smallpox 
vaccine being put to practical use?
In terms of vaccine design, it’s just too 
early. Most of the things we’ve been 
publishing have just been in the past 
couple of years. But there is an interest 
in having a cure for smallpox and 
monkeypox from a bioterrorism per-
spective. There’s a vaccine stockpile, 
but it would also be nice to have a 
cure if smallpox did show up. There 
were clinical trials back in the 1960s 
where they took antibodies from one 
person and transferred them into people 
who were exposed to smallpox, and it 
had about a 75% cure rate. Now that 
we know the key antibody targets for 
smallpox, we’ve made fully human 
monoclonal antibodies to them. We’ve 
got an NIH grant to do this because 
we’ve already shown in mice that these 
monoclonals protect against poxvirus 
infection. So, we recently manufactured 
a big batch of protective monoclonal 
antibodies. You know, it’s a bizarre 
project. We’re working hard to make 
something that we hope never actually 
gets used.
If you were given unlimited money from 
the government for immunology research, 
what would you spend it on?
I suppose if it were up to me, I would 
put more emphasis and money in the 
area of vaccine immunology, particu-
larly on studying it as a component of 
human immunology. I’m certainly not 
the only person saying that. Mark Davis 
had an opinion piece in Immunity in 
December that said what a lot of people 
have been saying and thinking, myself 
included, which is that 
mice are great, but we’ve 
really got to know human 
immunology a lot better. 
In theory, we’ve got tech-
niques and ways to do this, 
but the experiments are 
expensive, and it’s tough to 
get grants funded because 
the experiments aren’t as 
clever and fun as all the 
things you can do in mice. But they’re 
hugely important. I defi  nitely  think 
that we need more emphasis on human 
immunology, and that is frequently 
constrained by money.
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B cells (green) interacting with CD4+ T cells (red) in the germinal center.
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